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Abstract Extramedullary plasmacytoma (EMP) arises
outside the bone marrow, particularly in the head and neck
region (nasopharynx, nose cavity, sinuses, and tonsils), and
can be associated with multiple myeloma (MM). Three
cases of EMP in the head and neck region are described: a
Wrst case describes an EMP of the subglottis 3 years after
treatment of MM, a second case of an EMP solitary in the
middle ear presenting as a jugular foramen syndrome, and a
third case of an EMP localised at the epiglottis, recurring at
the Xoor of the nose cavity. Treatment of each EMP was sur-
gical. We reviewed literature about aetiology, clinical
course, diagnostics, treatment and prognosis. Important pre-
senting symptoms vary from epistaxis, rhinorrhoea, a sore
throat, dysphonia to haemoptoea. Association with MM
must be conWrmed or excluded. Histopathological examina-
tion, with immunological staining or Xow cytometry con-
Wrms the diagnosis. CT and MRI are useful in staging EMP.
The treatment of EMP is surgery and/or radiotherapy. The
prognosis depends on tumour size (>5 cm) and nodal
involvement. The 10-year survival rate is 50–80%.
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Introduction
Plasmacell disorders are characterised by the accumulation
of monoclonal plasmacells that all produce the same
immunoglobulin [1]. Plasmacytomas are plasmacell
tumours. They can occur solitary outside the bone marrow
[solitary bone plasmacytomas (SBP), solitary extramedul-
lary plasmacytomas (EMP)], but can also be associated
with multiple myeloma (MM) [2–4]. EMPs account for 4%
of all non-epithelial tumours of the upper respiratory tract
[5]. They arise submucosally (80%), in particular at the
nasopharynx, nose cavity, sinuses and tonsils.
The median age of presentation of EMP is 55 years and
75% of patients are men; 80% is localised in the head and
neck region (nose, sinuses, and nasopharynx). Other local-
isations are the gastro-intestinal tract, lungs, mammae,
testes and skin [6–9]. The most important presenting
symptoms are epistaxis, rhinorrhea, sore throat, dysphonia
and haemoptysis [1, 2, 8–14]. CT and/or MRI is used in
monitoring the adhering lymph nodes and bone structures
that can also be aVected, in particular the nasal cavity and
maxillary sinuses [8]. On histopathological investigation,
dense plasmacells with a monotone aspect are often pres-
ent. They possess a round to oval nucleus with a vesicular
nuclear chromatin pattern. The nucleus is often located
eccentrically in the cytoplasm (perinuclear halo) [15, 16].
Immunohistochemistry and Xow cytometry help diVerenti-
ate EMP from other entities, because EMP is composed of
plasmacells that also express CD138 and cytoplasmatic
light chains of type  or . Negative stainings for CD20 and
positive stainings for CD79 can support this diagnosis.
Hotz reported 14 out of 24 patients with EMP in the head
and neck region, with a monoclonal lesion after immuno-
histochemistry. In the other ten patients a reactive poly-
clonal plasmacytosis was conWrmed [15].
There is an association between diVerent monoclonal
gammopathies: MM, monoclonal gammopathy of undeter-
mined signiWcance (MGUS), asymptomatic myeloma (SMM),
indolent multiple myeloma (IMM), SBP, Waldenström
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disorders [17–21]. Hussong however, recently suggested that
EMP represents a form of extranodal marginal lymphoma
that has undergone extensive plasmacytic diVerentiation [21].
In addition to the main plasmacell component, histology also
shows characteristics of marginal zone lymphomas: reactive
follicles, lymphoepithelial lesions, centrocyt-like cells, and
monocytoid cells [10, 15]. Wiltshaw described an association
between MM and EMP 25 years ago, but also a predilection
for submucosal extension, the incidence of spread to other
soft tissues and the rare aVection of bone marrow [22].
The treatment of EMP consists of radiotherapy and/or sur-
gery. The prognosis after radical surgical resection is similar
for radiotherapy. In non-radicality, the additional value of
radiotherapy is not proven [2]. Many consider the combina-
tion of surgery and radiotherapy as treatment of choice.
The next cases describe three patients with plasmacyto-
mas at the ears, nose and throat.
Case 1
A 62-year-old woman was referred to a tertiary reference
centre with stridor. Her medical history described a MM
stage IIIb, treated with autologous stemcell transplantation
and chemotherapy (adriamycin, vincristine, dexametha-
sone) 3 years ago. Due to MM, she still used prednisone
10 mg daily. B-symptoms, recent upper respiratory tract
infection or a previous intubation were not present. Flexi-
ble laryngoscopy showed a subglottic stenosis with an
estimated rest lumen of 10%. A CT-scan of the neck and
videoXuoroscopy conWrmed this stenosis (Figs. 1, 2). No
abnormalities were found with laboratory investigation, in
particular no anaemia, no hypercalcaemia and no renal func-
tion disorders. A protein spectrum and immunohistological
staining showed a rise of monoclonal immunoglobulins,
type .
The patient underwent an open tracheotomy and a laryn-
gotracheoscopy with biopsy. Here, a horseshoe-shaped ste-
nosis was observed at the subglottis with a cranial-caudal
length of 1.5 cm, a solid consistency and a free anterior
border. Biopsies showed superWcial atypical inXammatory
cells and were not conclusive.
Thereafter, a laryngoWssure was performed. Loose pur-
ple-coloured tissue was found, from which material was
obtained with a curette for histopathological examination
(Fig. 3). A Montgomery T-tube was placed to preserve the
laryngeal lumen (Fig. 4). Immunohistochemical staining of
Fig. 1 Case 1 CT-scan neck. 
Sagital, coronal and axial views 
show a subglottic stenosis of the 
trachea, with a free anterior 
border caused by EMP123
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were conclusive for an IgG  monoclonal plasmacytoma
(Fig. 5). We diagnosed an EMP as a metastasis of MM. The
patient’s history was discussed in the multidisciplinary
head and neck oncology meeting and she was additionally
treated with chemotherapy (Thalidomide). Until now
(1 year later), there is an unchanged normal value of mono-
clonal immunoglobulin.
Case 2
A 72-year-old man, with a medical history of insulin-
dependent diabetes and tuberculosis, visited the referring
clinic with mastoiditis on the right ear, for which antibiotic
treatment was started. Four months later, he again com-
plained of otalgia, with normal otoscopical Wndings. After
an initial expectative management, a facial nerve-paralysis
occurred. A prednisolone declining scheme (according to
Taverner) and valaciclovir 500 mg three-times daily was
started.
An additional serological investigation showed no sero-
conversion for one of the neurotrope viruses or for Borrelia
Burgdorferi. The otalgia persisted and an MRI-scan of the
skull base was performed. This showed consolidation of the
mastoid cells, consisting with mastoiditis and a higher sig-
nal intensity of the sinus sigmoideus. The patient was
referred to our institution and underwent a posterior tympa-
notomy with exploration of the mastoid part of the facial
nerve. The covering vessels were visible and no attempt
was made for decompression. In the facial recess, tissue
was found which impressed as granulation tissue. Frozen
biopsy showed reactive connective tissue with a chronic
plasmacellular inXammation with no signs of malignancy
or malignant lymphoma.
The clinical course worsened however. The patient com-
plained of headaches and a complete facial nerve paralysis
developed (HB grade VI/VI). Simultaneously, a paresis
occurred of the glossopharyngeal, the vagus and the hypo-
glossal nerve (Fig. 6). A CT-scan with technetium of the
mastoid, showed osteolytical changes at the jugular fora-
men. Angiography was not suspicious for thrombosis of the
sigmoid sinus. To clearly expose the jugular foramen, an
infratemporal fossa approach according to Fisch type A
was performed. The facial nerve was surgically decom-
pressed, a punction of the sigmoid sinus was obtained and
the jugular foramen was explored. Medial from the jugular
foramen and also medial of the stylomastoid foramen, vitre-
ous tumour tissue was found, with a diVerent aspect than
the before removed granulation tissue. Histological investi-
gation showed a plasmacellular inWltrate, suspicious for a
solitary plasmacytoma, with polyclonal immunoglobulin
expression.
Additional analysis by means of lumbar punction, a skeletal
survey and Bence–Jones protein in urine, were all without
abnormalities. Post-operative, the headaches disappeared and
Fig. 2 Case 1 videostroboscopy subglottic stenosis caused by EMP,
with free anterior border (horseshoe shaped)
Fig. 3 Case 1 histopathology. Tissue sampling of EMP at the subglot-
tis: dense plasmacells with a monotone aspect; round, oval nuclei with
a radiated chromatin pattern, eccentric in the cytoplasm (perinuclear
halo)
Fig. 4 Montgomery T-tube123
1420 Eur Arch Otorhinolaryngol (2008) 265:1417–1423the facial nerve paresis declined to HB grade II/VI. The fora-
men jugular syndrome in combination with the eVects of radio-
therapy however, caused swallowing disorders for which a
percutaneous gastrostomy was needed. A year after treatment
the patient died of general discomfort.
Case 3
A 57-year-old man visited a referring clinic with a lesion of
the epiglottis suspected for plasmacytoma. An excision
biopsy was performed. Histological investigations sup-
ported the diagnosis: a dense proliferation of cells with
round to oval, eccentric located nuclei and radiated chroma-
tin pattern was seen. Additional immunohistochemical
investigation of the tumour cells was positive for CD138
and showed monoclonality for  light chains.
The patient was referred to our clinic. A lesion of 5 mm
was seen at the laryngeal side of the epiglottis. This was
microlaryngoscopically excised with laser. Bronchoscopy
and esophagoscopy were normal. Immunohistochemical
investigations of the removed tissue, showed an inXamma-
tory pseudo-polyp, positive for  and  light chains. It con-
cerned a polytypical plasmacell inWltrate. This was not
consistent with a suspected rest localisation of plasmacy-
toma. During outpatient follow-up, 2 months later, the
patient complained of haemoptoea. Internal and pulmonary
analysis did not show any focus of bleeding or signs of
MM, nor an endobronchial lesion. Examination of head and
neck did not show any abnormalities in particular at the lar-
ynx. However, a round, bowl-shaped tumour was seen at
the Xoor of the nose. A laryngo-, pharyngoscopy and
inspection of the mouth was carried out without abnormali-
ties. A subsequent nasendoscopy showed a tumour at the
Fig. 5 Case 1 immunohisto-
chemical staining. a Positive 
staining of CD138; b positive 
staining for kappa light chains
Fig. 6 Case 2 the left picture 
shows a complete right-sided fa-
cial nerve paresis. The right pic-
ture shows a paresis of the 
hypoglossal nerve; the tongue is 
protruded123
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excised. Histopathological investigation showed a classic
morphology indicating EMP.
Outpatient controls 1 month after the last intervention,
showed a new lesion at the left plica ary-epiglottica. Due to
the two macroscopically removed plasmacytomas and the
clinical suspicion of a new third location, radiotherapy of
larynx, hypopharynx and nasopharynx was started with a
total dose of 50 Gy. Haematological analysis by means of
immunological, laboratory (total IgG, total IgA, total pro-
tein urine and protein spectrum), bone marrow aspiration
and bone biopsy, showed no signs of MM. Two years after
original presentation, this patient is still free of  disease.
Discussion
Case 1 describes an EMP as recurrence of MM. MM is next
to non-Hodgkin lymphoma the most occurring haematolog-
ical malignancy (10%) [23]. It accounts for 1% of all
malignancy and 2% of the total malignancy-related mortal-
ity. Incidence rates are higher in men and increase in age, in
particular between age 65 and 70. MM develops in the
post-germinal centres of B-lymphocytes. This concerns
often IgG, associated with kappa- and lambda light chains.
With electrophoresis, an elevated serum paraprotein
[monoclonal protein (M-protein), e.g. Beta2-microglobu-
lin] can be shown, just as Bence–Jones protein in urine.
Next to laboratory investigations, the work-up also includes
radiological analysis of the axial skeletal system [17–21].
In 2003, the International Myeloma Working Group [17]
published diagnostic criteria for symptomatic and asymp-
tomatic MM, and for MGUS. EMP is characterised by an
extramedullary located mass inWltrated by monoclonal
plasmacells without signs of MM elsewhere in the body
(Table 1). A SBP is a solitary bone lesion without signs of
other bone lesions on X-ray survey and without plasmacy-
tosis in the bone marrow.
CT or MRI with technetium contrast can diVerentiate
between inXammatory tissue and/or tumours [24, 25]. His-
tological investigations by means of light microscopy of the
obtained tissue oVers diVerentiation between reactive plas-
macytosis, plasmacell granulomas, bad diVerentiated neo-
plasms, immunoblastic lymphomas and mucosa-associated
lymphomas (MALT) [15, 16]. DiVerentiation between
EMP and MM is important for the prognosis. The treatment
is systemic [26]. Besides serum and urine analysis, histo-
chemical peroxidase–anti-peroxidase stainings oVer help
diVerentiating EMP and MM. Until now, an approximate
100 cases of EMP are reported in literature [26–33] of
which 25 as metastasis of MM [34–37]. The diagnosis of
laryngeal EMP is diYcult because of the non-speciWc
symptoms and the mucosa covering the tumour [33].
Case 2 concerns a plasmacytoma of the middle ear with
extension to the jugular foramen and the temporal bone.
The extension to the jugular foramen causes the so-called
jugular foramen syndrome (paralysis of the cranial nerves
IX, X, XI and eventually XII). The most important processes
Table 1 Criteria EMP, 
symptomatic multiple myeloma, 
asymptomatic myeloma and 
monoclonal gammopathy 
of undetermined signiWcance 
[11, 17]
Criteria EMP [11]
• Solitary extramedullary mass inWltrated by monoclonal plasmacells
• Absence of morphological and immunophenotypical Wndings suggestive for reactive plasmacytosis, 
bad diVerentiated epithelial tumours, immunoblastic lymphoma and lymphoplasmatic lymphoma
• Normal bone marrow aspiration and biopsy
• Normal results on a radiological skeletal survey and MRI of vertebral column and hip
• No anaemia, hypercalcaemia or kidney disorders caused by a proliferative plasmacell disorder
International Myeloma Working Group [17]
Criteria symptomatic multiple myeloma
• >10% clonal plasmacells [bone marrow biopsy or elsewhere (plasmacytoma)]
• Monoclonal protein (paraprotein) in serum or urine: >30 g/L
• End-organ damage: hypercalcaemia, renal insuYciency, anaemia, bone lesions (or osteoporosis), 
frequent infections (>2 per years), amyloidosis elsewhere, hyperviscosity syndrome
Criteria asymptomatic myeloma
• Serum paraprotein >30 g/L and/or
• Clonal plasmacells >10% in bone marrow biopsy and
• No myeloma related organ failure
Criteria monoclonal gammopathy of undetermined signiWcance
• Serum paraprotein <30 g/L and/or
• Clonal plasmacells <10% in bone marrow biopsy and
• No myeloma related organ failure123
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meningioma, periferical primitive neuro-ectodermale tumour,
chondrosarcoma, chordoma, chondroblastoma, giant-cell
tumour, endolymphatic sac tumour cholesterol granuloma,
reactive myoWbroblastic tumour, temporal bone carcinoma
and Wnally malignant external otitis. Radiologically these
processes are diagnosed by means of CT-scan (bone win-
dow), MRI and angiography before surgery [38]. Tissue
sampling remains necessary. This is not always obvious
due to unusual locations of EMP’s.
In Case 3, EMP is recurrent. Independent of the previ-
ous location, recurrence occurs. This is important in the
follow-up of EMP. About this, no guidelines are avail-
able in literature. Additional radiotherapy seems eVec-
tive. In less than 5% of patients, EMP’s are recurrent.
There seems to be a relation between tumour size of
>5 cm and the recurrence rate. In nodal aVection, this rate
is higher. One advises to treat lymph nodes also with
radiotherapy [39]. In current literature, no advantages of
administration of chemotherapy before or after radiother-
apy are found [9].
In approximately 30% of treated patients distant failure
seem to occur. This takes place on average within 2–3 years
after diagnosis [6–9]. Progression is characterised by bone
lesions, bone marrow plasmacytosis and high monoclonal
protein levels; 15% develops MM, some however develop
multiple EMPs without intervening bone marrow plasma-
cytosis [10]. The most common sites for soft tissue involve-
ment are the lymph node, skin and subcutaneous tissues
[22]. Also bone lesions can occur [9]. In MM and SBP,
bone involvement is usually within the axial skeleton. In
contrast, in EMP, bone lesions seem to be distributed ran-
domly throughout the skeleton [10]. Prognostic variables
are hard to clarify due to the small numbers of patients in
published series. Adjacent bone destruction may worsen the
prognosis in EMP [13], however this diVerence has not
always been conWrmed [8, 14, 40]. There is also a trend of
more frequent dissemination of EMP arising outside the
head and neck region [9], for example pulmonary EMP.
Most patients die of non-EMP related disorders and more
than two-thirds of patients survive for more than 10 years
[6–9].
Conclusion
EMP is a disorder of monoclonal immunoglobulines pre-
senting as plasmacytomas in the head and neck region in
particular. Locations are diverse, mostly aVecting nose and
nasopharynx, but also larynx and mastoid. Prognosis
depends on the extension of the EMP and on laboratory
Wndings. Treatment exists of radiotherapy, eventually
preceeded by surgery. The prognosis is not unfavourable.
Diagnosis and diVerentiation of other tumours in the head
and neck region is important.
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